These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34792486)

  • 1. Treatment of acromegaly has substantial effects on body composition: a long-term follow-up study.
    Wolf P; Salenave S; Durand E; Young J; Kamenicky P; Chanson P; Maione L
    Eur J Endocrinol; 2021 Dec; 186(2):173-181. PubMed ID: 34792486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Body composition in active acromegaly during treatment with octreotide: a double-blind, placebo-controlled cross-over study.
    Hansen TB; Gram J; Bjerre P; Hagen C; Bollerslev J
    Clin Endocrinol (Oxf); 1994 Sep; 41(3):323-9. PubMed ID: 7955439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
    Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition.
    Reid TJ; Jin Z; Shen W; Reyes-Vidal CM; Fernandez JC; Bruce JN; Kostadinov J; Post KD; Freda PU
    Pituitary; 2015 Dec; 18(6):808-19. PubMed ID: 25907335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of GH-IGF-I excess and gonadal status on bone mineral density and body composition in patients with acromegaly.
    Madeira M; Neto LV; de Lima GA; Moreira RO; de Mendonça LM; Gadelha MR; Farias ML
    Osteoporos Int; 2010 Dec; 21(12):2019-25. PubMed ID: 20306022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly.
    Parkinson C; Whatmore AJ; Yates AP; Drake WM; Brabant G; Clayton PE; Trainer PJ
    Clin Endocrinol (Oxf); 2003 Aug; 59(2):168-74. PubMed ID: 12864793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
    Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk.
    Reyes-Vidal C; Fernandez JC; Bruce JN; Crisman C; Conwell IM; Kostadinov J; Geer EB; Post KD; Freda PU
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4124-32. PubMed ID: 25137427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex Does Not Affect Changes in Body Composition and Insulin-Like Growth Factor-I During US Army Basic Combat Training.
    Roberts BM; Staab JS; Caldwell AR; Sczuroski CE; Staab JE; Lutz LJ; Reynoso M; Geddis AV; Taylor KM; Guerriere KI; Walker LA; Hughes JM; Foulis SA
    J Strength Cond Res; 2024 Jun; 38(6):e304-e309. PubMed ID: 38320231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in insulin-like growth factor-I and -II associated with fat but not lean mass in early old age.
    Bann D; Holly JM; Lashen H; Hardy R; Adams J; Kuh D; Ong KK; Ben-Shlomo Y
    Obesity (Silver Spring); 2015 Mar; 23(3):692-8. PubMed ID: 25645314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations between body composition, circulating interleukin-1 receptor antagonist, osteocalcin, and insulin metabolism in active acromegaly.
    Ueland T; Fougner SL; Godang K; Lekva T; Schurgers LJ; Scholz H; Halvorsen B; Schreiner T; Aukrust P; Bollerslev J
    J Clin Endocrinol Metab; 2010 Jan; 95(1):361-8. PubMed ID: 19880791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone metabolism and body composition in Japanese patients with active acromegaly.
    Kaji H; Sugimoto T; Nakaoka D; Okimura Y; Kaji H; Abe H; Chihara K
    Clin Endocrinol (Oxf); 2001 Aug; 55(2):175-81. PubMed ID: 11531923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lowered ghrelin levels in acromegaly—normalization after treatment].
    Kozakowski J; Rabijewski M; Zgliczyński W
    Endokrynol Pol; 2005; 56(6):862-70. PubMed ID: 16821203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic health of young adults who were born small for gestational age and treated with growth hormone, after cessation of growth hormone treatment: a 5-year longitudinal study.
    van der Steen M; Smeets CC; Kerkhof GF; Hokken-Koelega AC
    Lancet Diabetes Endocrinol; 2017 Feb; 5(2):106-116. PubMed ID: 28011067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skeletal muscle mass in acromegaly assessed by magnetic resonance imaging and dual-photon x-ray absorptiometry.
    Freda PU; Shen W; Reyes-Vidal CM; Geer EB; Arias-Mendoza F; Gallagher D; Heymsfield SB
    J Clin Endocrinol Metab; 2009 Aug; 94(8):2880-6. PubMed ID: 19491226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.
    Cardinal T; Rutkowski MJ; Micko A; Shiroishi M; Jason Liu CS; Wrobel B; Carmichael J; Zada G
    Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Body composition and energy expenditure in acromegaly.
    O'Sullivan AJ; Kelly JJ; Hoffman DM; Freund J; Ho KK
    J Clin Endocrinol Metab; 1994 Feb; 78(2):381-6. PubMed ID: 8106626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine.
    Kayath MJ; Vieira JG
    Osteoporos Int; 1997; 7(3):226-30. PubMed ID: 9205635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant.
    Drake WM; Rowles SV; Roberts ME; Fode FK; Besser GM; Monson JP; Trainer PJ
    Eur J Endocrinol; 2003 Dec; 149(6):521-7. PubMed ID: 14640992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adipocytes as a source of increased circulating levels of nicotinamide phosphoribosyltransferase/visfatin in active acromegaly.
    Olarescu NC; Ueland T; Lekva T; Dahl TB; Halvorsen B; Aukrust P; Bollerslev J
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1355-62. PubMed ID: 22319029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.